Comorbid cancer and use of thrombolysis in acute pulmonary embolism
- 17 November 2018
- journal article
- research article
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 47 (2) , 324-327
Abstract
Guidelines suggest the use of thrombolytic therapy for acute pulmonary embolism (PE) patients with hypotension who are not at high-risk of bleeding. Data describing the use of thrombolysis in patients with cancer are scarce. The aim of this study was to evaluate the relationship between cancer and the use of thrombolysis for acute PE. The 2013 and 2014 US National Inpatient Sample was used to identify admissions for acute PE. Identified admissions were stratified based on the presence or absence of cancer. Multivariable logistic regression was performed to determine the association between comorbid cancer and the odds of receiving thrombolysis after adjustment for patient- and hospital-level covariates. In those receiving thrombolysis, the association between cancer and in-hospital mortality was determined using logistic regression after adjusting for age ≥ 65 years and sex. We identified 72,546 admissions for acute PE; of which, 14.7% (n = 10,673) had comorbid cancer. A total of 3.4% (n = 2439) of patients received thrombolysis. Upon multivariable adjustment, cancer was associated with decreased odds of receiving thrombolysis (odds ratio = 0.55; 95% confidence interval = 0.48–0.64). When the population was restricted to PE admissions receiving thrombolysis, mortality occurred in 315 (12.9%) admissions; with no difference in in-hospital mortality observed between those with versus without cancer (p = 0.11). In this study of admissions for acute PE, comorbid cancer was associated with decreased odds of receiving thrombolysis. As PE is a common complication among patients with cancer, the risk–benefit profile of thrombolysis in this patient population should be determined.Keywords
This publication has 10 references indexed in Scilit:
- Clinical presentation and in-hospital death in acute pulmonary embolism: does cancer matter?Internal and Emergency Medicine, 2016
- Antithrombotic Therapy for VTE DiseaseChest, 2016
- The role of thrombolytic therapy in pulmonary embolismBlood, 2015
- Thrombolysis in hemodynamically stable patients with acute pulmonary embolism: A meta-analysisThrombosis Research, 2014
- Thrombolysis for Pulmonary Embolism and Risk of All-Cause Mortality, Major Bleeding, and Intracranial HemorrhageJAMA, 2014
- Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysisEuropean Heart Journal, 2014
- Impact of the efficacy of thrombolytic therapy on the mortality of patients with acute submassive pulmonary embolism: a meta‐analysisJournal of Thrombosis and Haemostasis, 2014
- A systematic review of validated methods for identifying venous thromboembolism using administrative and claims dataPharmacoepidemiology and Drug Safety, 2012
- Comorbidity Measures for Use with Administrative DataMedical Care, 1998
- Venous thromboembolism and cancer A two-way clinical associationFrontiers in Bioscience-Landmark, 1997